
    
      This is an open-label, flexibly-dosed, 26 week extension study in children and adolescents
      with ADHD who have completed 6 weeks of double-blind treatment in the core study (SEP360
      202). This study will evaluate the long-term safety and tolerability of dasotraline in this
      population.
    
  